BIIB34:BVMF
Biogen Inc BDR
184,49 R$
0,00%
(0,00) 1 d.
5. okt., 15:59:13 GMT-3 · BRL
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: BIIB34…
Tirgus kapitalizācija
32,39 mljrd.
Vid. apjoms
7,00
Apjoms
0,00
Augstākā 52 ned.
191,00 R$
Zemākā 52 ned.
128,69 R$
Apgrozībā esošās akcijas
147,75 milj.
Darbinieku skaits
8 tūkst.
Tirgus kapitalizācija
32,39 mljrd.
Vid. apjoms
7,00
Apjoms
0,00
Augstākā 52 ned.
191,00 R$
Zemākā 52 ned.
128,69 R$
Apgrozībā esošās akcijas
147,75 milj.
Darbinieku skaits
8 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Pluang
·
pirms 3 stundām
Biogen expected to slightly beat Q3 earnings wi...
Yahoo Finance
·
pirms 4 stundām
Biogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies says
AD HOC NEWS
·
pirms 14 stundām
Biogen reports lupus data while Biogen stock trades at EUR 199.33
Kalkine Media
·
pirms 1 dienas
Biogen's Chief Accounting Officer Sean Godbout Reports October 2026 Stock Transactions via Form 4
Profils
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
Par “Biogen Inc BDR”
ĢenerāldirektorsChris Viehbacher
Darbinieki7,5 tūkst.
Dibināšanas datums1978
Galvenais birojsKeimbridža, Masačūsetsa, Amerikas Savienotās Valstis
Sektors-
Tīmekļa vietnebiogen.com